Citations

Clear

1446 citation(s) found for "Howard, F".

Differential regulation of amino acid exchange and protein dynamics across splanchnic and skeletal muscle beds by insulin in healthy human subjects.
Persson, M., Ford, G. C., Nair, K. S., Meek, Sarah

Mayo Clinic

Diabetes | March 6, 2007 | Volume: 47 | Issue: 12 | Pages: 1824-1835

10.2337/diabetes.47.12.1824 | PMID 9836512 Get It

To define the mechanism of insulin's anticatabolic action, the effects of three different dosages of insulin (0.25, 0.5, and 1.0 mU x kg(-1) x min(-1)) versus saline on protein dynamics across splanchnic and skeletal muscle (leg) beds were determined using stable isotopes of phenylalanine, tyrosine, and leucine in 24 healthy subjects. After an overnight fast, protein breakdown in muscle exceeded protein synthesis, causing a net release of amino acids from muscle bed, while in the splanchnic bed protein synthesis exceeded protein breakdown, resulting in a net uptake of these amino acids. Insulin decreased (P < 0.003) muscle protein breakdown in a dose-dependent manner with no effect on muscle protein synthesis, thus decreasing the net amino acid release from the muscle bed. In contrast, insulin decreased protein synthesis (P < 0.03) in the splanchnic region with no effect on protein breakdown, thereby decreasing the net uptake of the amino acids. In addition, insulin also decreased (P < 0.001) leucine nitrogen flux substantially more than leucine carbon flux, indicating increased leucine transamination (an important biochemical process for nitrogen transfer between amino acids and across the organs), in a dose-dependent manner, with the magnitude of effect being greater on skeletal muscle than on the splanchnic bed. In conclusion, muscle is in a catabolic state in human subjects after an overnight fast and provides amino acids for synthesis of essential proteins in the splanchnic bed. Insulin achieves amino acid balance across splanchnic and skeletal muscle beds through its differential effects on protein dynamics in these tissue beds.
Phase III Trial of Carmustine and Cisplatin Compared With Carmustine Alone and Standard Radiation Therapy or Accelerated Radiation Therapy in Patients With Glioblastoma Multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group
Buckner, Jan C. , Michalak, John C., Burton, Gary V., Cascino, Terrence L., Schomberg, Paula J., Hawkins, Roland B., Scheithauer, Bernd W., Marks, Randolph S., OʼFallon, Judith R., Ballman, Karla V. , Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | August 18, 2006 | Volume: 24 | Issue: 24 | Pages: 3871-3879

10.1200/jco.2005.04.6979 | PMID 16921039 Get It

Purpose In patients with newly diagnosed glioblastoma multiforme, to determine whether cisplatin plus carmustine (BCNU) administered before and concurrently with radiation therapy (RT) improves survival compared with BCNU and RT and whether survival using accelerated RT (ART) is equivalent to survival using standard RT (SRT). Patients and Methods After surgery, patients were stratified by age, performance score, extent of surgical resection, and histology (glioblastoma v gliosarcoma) and then randomly assigned to arm A (BCNU plus SRT), arm B (BCNU plus ART), arm C (cisplatin plus BCNU plus SRT), or arm D (cisplatin plus BCNU plus ART). Results Four hundred fifty-one patients were randomly assigned, and 401 were eligible. Frequent toxicities included myelosuppression, vomiting, sensory neuropathy, and ototoxicity and were worse with cisplatin. There was no difference in toxicity between SRT and ART. Median survival times and 2-year survival rates for patients who received BCNU plus RT (arms A and B) compared with cisplatin, BCNU, and RT (arms C and D) were 10.1 v 11.5 months, respectively, and 11.5% v 13.7%, respectively (P = .19). Median survival times and 2-year survival rates for patients who received SRT (arms A and C) compared with ART (arms B and D) were 11.2 v 10.5 months, respectively, and 13.8% v 11.4%, respectively (P = .33). Conclusion Cisplatin administered concurrently with BCNU and RT resulted in more toxicity but provided no significant improvement in survival. SRT and ART produced similar toxicity and survival.
P1–310: Late onset Alzheimer's disease (LOAD) susceptibility alleles in the insulin–degrading–enzyme gene (IDE) and other Aβ–degrading enzymes
Carrasquillo, Minerva M. , Kashino, Mariah R., Wilcox, Samantha L., Howard, Melissa E., Li, Ma, Zou, Fanggeng, Ertekin‐Taner, Nilüfer , Allen, Mariet , Younkin, Linda H., Petersen, Ronald C. , Younkin, Steven G., Carrasquillo, Minerva M. , Younkin, Samuel , Dincman, Toros A. , Stanton, Chloë M. , Watson, Christopher Mark , Graff, Caroline

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_7 | Pages: No page available

10.1016/j.jalz.2006.05.688 Get It

Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: What have we learned?
Grundman, Michael, Petersen, Ronald C. , Bennett, David A. , Feldman, Howard , Salloway, Stephen , Thal, Leon J., Schenk, Dale, Khachaturian, Zaven S., Thies, William, Visser, Pieter Jelle , Bennett, David A. , Feldman, Howard H

Mayo Clinic

Alzheimer's & Dementia | June 14, 2006 | Volume: 2 | Issue: 3 | Pages: 220-233

10.1016/j.jalz.2006.04.010 | PMID 19595891 Get It

The biological changes that occur in the brains of Alzheimer's disease (AD) patients are thought to begin long before the onset of clinical symptoms. Although current therapeutic agents have been approved only for patients with mild to moderate AD, Alzheimer‐type pathology in patients with mild to moderate AD is already quite advanced. One impetus for the development of the concept of mild cognitive impairment (MCI) was the attempt to recognize AD early in its clinical expression and to determine whether it is possible through therapeutic interventions to improve the memory impairment at this stage or delay further progression to dementia. To this end, several clinical trials have been conducted in patients with MCI. On September 8 and 9, 2004 a meeting of the Alzheimer's Association Research Roundtable was held at which experts in the field of MCI convened to review the collective experience from these trials and to consider potential approaches that might improve MCI clinical trials in the future. This article summarizes the presentations and discussions of that meeting.
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward
Kelloff, Gary J. , Lippman, Scott M. , Dannenberg, Andrew J. , Sigman, Caroline C. , Pearce, Homer L., Reid, Brian J. , Szabó, Éva , Jordan, V. Craig , Spitz, Margaret R., Papadimitrakopoulou, Vali A., Lotan, Reuben, Aggarwal, Bharat B. , Bresalier, Robert S. , Kim, Jeri , Lu, Karen H. , Thomas, Melanie E., Rhodes, Helen, Brewer, Molly, Follen, Michele , Shin, Dong M. , Parnes, Howard L. , Siegfried, Jill M. , Evans, Alison A., Blot, William J. , Chow, Wong‐Ho , Blount, Patricia L., Wang, Kenneth K. , Lam, Stephen , Lee, J. Jack, Dubinett, Steven M., Engstrom, Paul F., Meyskens, Frank L. , O’Shaughnessy, Joyce , Hawk, Ernest T. , Levin, Bernard, Nelson, William G. , Hong, Waun Ki , Prevention, for the AACR Task Force on Cancer, Lee, J. Jack , Mills, Gordon B. , Arun, Banu , Maley, Carlo C. , Lee, J. Jack, Prevention, for the AACR Task Force on Cancer, Szabo, Eva , Lee, J Jack

Mayo Clinic

Clinical Cancer Research | June 8, 2006 | Volume: 12 | Issue: 12 | Pages: 3661-3697

10.1158/1078-0432.ccr-06-1104 | PMID 16778094 Get It

AbstractThis article reviews progress in chemopreventive drug development, especially data and concepts that are new since the 2002 AACR report on treatment and prevention of intraepithelial neoplasia. Molecular biomarker expressions involved in mechanisms of carcinogenesis and genetic progression models of intraepithelial neoplasia are discussed and analyzed for how they can inform mechanism-based, molecularly targeted drug development as well as risk stratification, cohort selection, and end-point selection for clinical trials. We outline the concept of augmenting the risk, mechanistic, and disease data from histopathologic intraepithelial neoplasia assessments with molecular biomarker data. Updates of work in 10 clinical target organ sites include new data on molecular progression, significant completed trials, new agents of interest, and promising directions for future clinical studies. This overview concludes with strategies for accelerating chemopreventive drug development, such as integrating the best science into chemopreventive strategies and regulatory policy, providing incentives for industry to accelerate preventive drugs, fostering multisector cooperation in sharing clinical samples and data, and creating public-private partnerships to foster new regulatory policies and public education.
Cyclosporin-mediated inhibition of bovine calcineurin by cyclophilins A and B.
Swanson, S, Born, Teresa L., Zydowsky, Lynne D., Cho, H, Chang, Howard Y. , Rusnak, Frank, Walsh, C.T.

Mayo Clinic

Proceedings of the National Academy of Sciences | May 31, 2006 | Volume: 89 | Issue: 9 | Pages: 3741-3745

10.1073/pnas.89.9.3741 | PMID 1315036 Get It

The Ca(2+)- and calmodulin-dependent protein phosphatase calcineurin is inhibited by the immunosuppressant drug cyclosporin A in the presence of cyclophilin A or B. Of the two isoforms, cyclophilin B is more potent by a factor of 2-5 when either the phosphoprotein [32P]casein or the [32P]phosphoserine [Ser(32P)] form of the 19-residue bovine cardiac cAMP-dependent protein kinase regulatory subunit peptide RII, [Ser(32P)15]RII, is used as substrate. With [Ser(32P15]RII as substrate, the concentrations of the cyclosporin A.cyclophilin A and cyclosporin A.cyclophilin B complexes, which cause 50% inhibition of calcineurin activity, are 120 and 50 nM, respectively. Lowering the concentration of calcineurin 80% with [32P]casein as substrate lowered the apparent inhibition constant for each complex even further; 50% inhibition of calcineurin was observed at 40 nM for cyclosporin A.cyclophilin A, whereas it was less than 10 nM for cyclosporin A.cyclophilin B. In all inhibition assays with [32P]casein or [Ser(32P)15]RII, the concentration of calcineurin required for measurable phosphatase activity is such that these complexes behave as tight-binding inhibitors of calcineurin, and steady-state kinetics cannot be used to assess inhibition patterns or Ki values. Limited trypsinization of calcineurin produces a fragment that is still inhibited, indicating that the interaction of cyclosporin.cyclophilin with calcineurin does not require either calmodulin or Ca2+.
An Otolaryngology, Neurology, Allergy, and Primary Care Consensus on Diagnosis and Treatment of Sinus Headache
Levine, Howard L., Setzen, Michael, Cady, Roger , Schreiber, Curtis P., Eross, Eric J., Blumenthal, Harvey J., Lumry, William R. , Berman, Gary , Durham, Paul L. , Dodick, David W.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | February 22, 2006 | Volume: 134 | Issue: 3 | Pages: 516-523

10.1016/j.otohns.2005.11.024 | PMID 16500456 Get It

While “sinus” headache is a widely accepted clinical diagnosis, many medical specialists consider it to be an uncommon cause of recurrent headaches. Unnecessary diagnostic studies, surgical interventions, and medical treatments are often the result of the inappropriate diagnosis of sinus headache. Both the International Headache Society and the American Academy of Otolaryngology–Head and Neck Surgery have attempted to characterize conditions leading to headaches of rhinogenic origin. However, they have done so from different perspectives and in isolation from the other specialty groups. An interdisciplinary ad hoc committee recently convened to discuss the role of sinus disease and the nose in the etiology of headache and to review recent epidemiologic studies suggesting that sinus headache (headache of rhinogenic origin) and migraine are frequently confused with one another. Clinical trial data are presented which clearly indicate that the majority of sinus headaches can actually be classified as migraines. This committee reviewed scientific evidence available from multiple disciplines and concludes that considerable research and clinical study are needed to further understand and explain the role of nasal pathology and autonomic activation in migraine and headaches of rhinogenic origin. However, there was a consensus from this group that greater diagnostic and therapeutic attention needs to be given to patients complaining of sinus headache that may indeed be due to the nose.
Bioactivity of Autologous Irradiated Renal Cell Carcinoma Vaccines Generated by Ex Vivo Granulocyte-Macrophage Colony-Stimulating Factor Gene Transfer
Simons, J.W., Weber, Christine E., Levitsky, H.J., Nelson, William G. , Lazenby, A, Cohen, Laura K., Finn, C. C., Clift, S , Hauda, Karen M., Leiferman, K M, Owens, Albert H., Piantadosi, Steven , Dranoff, Glenn , Mulligan, Richard C., Pardoll, Drew M. , Marshall, Fray F., Jaffee, Elizabeth M. , Carducci, Michael A. , Beck, Lisa A.

Mayo Clinic

Journal of Urology | January 17, 2006 | Volume: 159 | Issue: 2S | Pages: 617-618

10.1016/s0022-5347(01)63906-5 Get It

YKL-40 Expression is Associated with Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma
Pelloski, Christopher E., Mahajan, Anita , Chang, Eric L. , Woo, Shiao Y. , Colman, Howard , Ledoux, Alicia A., Blair, Hilary, Passe, Sandra, Jenkins, Robert B. , Aldape, Kenneth , Maor, Moshe , Gilbert, Mark R. , Colman, Howard , Yang, Helen

Mayo Clinic

Clinical Cancer Research | September 21, 2005 | Volume: 11 | Issue: 9 | Pages: 3326-3334

10.1158/1078-0432.ccr-04-1765 | PMID 15867231 Get It

Abstract Purpose: YKL-40 is a secreted protein that has been reported to be overexpressed in epithelial cancers and gliomas, although its function is unknown. Previous data in a smaller sample set suggested that YKL-40 was a marker associated with a poorer clinical outcome and a genetically defined subgroup of glioblastoma. Here we test these findings in a larger series of patients with glioblastoma, and in particular, determine if tumor YKL-40 expression is associated with radiation response. Experimental Design: Patients (n = 147) with subtotal resections were studied for imaging-assessed changes in tumor size in serial studies following radiation therapy. An additional set (n = 140) of glioblastoma patients who underwent a gross-total resection was tested to validate the survival association and extend them to patients with minimal residual disease. Results: In the subtotal resection group, higher YKL-40 expression was significantly associated with poorer radiation response, shorter time to progression and shorter overall survival. The association of higher YKL-40 expression with poorer survival was validated in the gross-total resection group. In multivariate analysis with both groups combined (n = 287), YKL-40 was an independent predictor of survival after adjusting for patient age, performance status, and extent of resection. YKL-40 expression was also compared with genetically defined subsets of glioblastoma by assessing epidermal growth factor receptor amplification and loss at chromosome 10q, two of the common recurring aberrations in these tumors, using fluorescent in situ hybridization. YKL-40 was significantly associated with 10q loss. Conclusions: The findings implicate YKL-40 as an important marker of therapeutic response and genetic subtype in glioblastomas and suggest that it may play an oncogenic role in these tumors.
MULTI-INSTITUTIONAL VALIDATION STUDY OF NEURAL NETWORKS TO PREDICT DURATION OF STAY AFTER LAPAROSCOPIC RADICAL/SIMPLE OR PARTIAL NEPHRECTOMY
Parekattıl, Sıjo J. , Gill, Inderbir S. , Castle, Erik P., Burgess, Scott V., Walls, M., Thomas, Raju , Kumar, Udaya , Purifoy, Jody Ann, Ng, Christopher, Fuchs, Gerhard, Weise, Erik S., Winfield, Howard N., Lallas, Costas D. , Andrews, Paul E. , Kang, Young Mi , Gill, Inderbir S

Mayo Clinic

Journal of Urology | September 13, 2005 | Volume: 174 | Issue: 4 Part 1 | Pages: 1380-1384

10.1097/01.ju.0000173921.67597.e8 | PMID 16145442 Get It